{"product_id":"mckesson-five-forces-analysis","title":"McKesson Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDon't Miss the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMcKesson faces intense supplier negotiations and evolving payer pressures, while scale and distribution breadth temper entrant threats—yet technology disruption and regulatory shifts keep competitive dynamics fluid.\u003c\/p\u003e\n\u003cp\u003eThis brief snapshot only scratches the surface. Unlock the full Porter's Five Forces Analysis to explore McKesson’s competitive dynamics, market pressures, and strategic advantages in detail.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Major Pharmaceutical Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe global pharmaceutical market is concentrated: the top 10 drugmakers held about 45% of global prescription drug revenue in 2024, so major suppliers exert strong leverage over distributors like McKesson because branded, high-demand drugs are must-stock items.\u003c\/p\u003e\n\u003cp\u003eSupplier power rose as 2023–2025 M\u0026amp;A cut the supplier pool—Biogen\/Samsung and other deals reduced alternative sources for specialty biologics, raising price and supply negotiation risk for McKesson.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent Protection and Exclusive Drug Rights\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturers of patented drugs hold legal monopolies—typically 12–20 years including exclusivities—blocking distributors from cheaper substitutes, so suppliers command strong pricing power.\u003c\/p\u003e\n\u003cp\u003eMcKesson must stock these branded, high-margin therapies to serve hospitals and clinics; in 2024 branded Rx accounted for about 28% of U.S. pharmaceutical spending, tightening supplier leverage.\u003c\/p\u003e\n\u003cp\u003eReliance on exclusives stays critical into 2026 as patent cliffs, biosimilar uptake (around 15% for top biologics by 2025) and contract terms shape distributor margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrowth of Complex Specialty and Biologic Medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe shift to specialty and biologic medicines—which made up about 50% of global drug spend in 2024 (IQVIA)—requires cold‑chain and specialty handling often specified by manufacturers, raising McKesson’s operational costs and compliance burdens.\u003c\/p\u003e\n\u003cp\u003eManufacturers increasingly use limited or exclusive distribution networks—estimates show top biologic launches use 1–3 preferred distributors—giving suppliers control over partner selection and margins.\u003c\/p\u003e\n\u003cp\u003eWith specialty drugs driving ~70% of US drug spend growth in 2023–24, manufacturers hold strong leverage in contract talks, squeezing distributor pricing flexibility and rebate structures.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Integrity and Manufacturing Quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMcKesson depends on suppliers that meet FDA, EMA and USP manufacturing standards, so a single plant shutdown can cause national SKU shortages; for example, 2023 FDA drug shortage reports showed 290 active shortages, highlighting systemic fragility.\u003c\/p\u003e\n\u003cp\u003eBecause McKesson is a downstream distributor, supplier quality failures reduce its ability to re-source quickly, raising suppliers' bargaining power and pricing leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e290 active drug shortages in 2023 (FDA)\u003c\/li\u003e\n\u003cli\u003eHigh compliance cost raises switching friction\u003c\/li\u003e\n\u003cli\u003eSingle-plant failures cause wide distribution impact\u003c\/li\u003e\n\u003cli\u003eSuppliers gain pricing and timing leverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBackward Integration by Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge pharma firms like Pfizer and Johnson \u0026amp; Johnson piloted direct-to-provider shipping in 2023–2025, cutting distributor volume by up to 5–8% in pilot markets and forcing distributors to defend margins.\u003c\/p\u003e\n\u003cp\u003eBy building in-house logistics or using niche 3PLs, suppliers lower dependence on McKesson and create credible backward-integration threats that cap McKesson’s supplier negotiation leverage.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePfizer\/J\u0026amp;J pilots 2023–25 reduced distributor share 5–8%\u003c\/li\u003e\n\u003cli\u003eSupplier 3PL partnerships rose ~12% CAGR 2020–24\u003c\/li\u003e\n\u003cli\u003eDisintermediation limits margin pressure McKesson can apply\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentrated drugmakers dominate pricing and supply amid shortages and low biosimilar uptake\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers hold strong bargaining power: top-10 drugmakers = ~45% global Rx revenue (2024), branded Rx ≈28% US spend (2024), specialty\/biologics ≈50% global spend (2024) and ~70% US spend growth (2023–24). M\u0026amp;A 2023–25 and limited distribution raise switching costs; FDA reported 290 active shortages (2023), biosimilar uptake ~15% (2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop-10 share\u003c\/td\u003e\n\u003ctd\u003e45% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBranded US spend\u003c\/td\u003e\n\u003ctd\u003e28% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty share\u003c\/td\u003e\n\u003ctd\u003e50% global (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug shortages\u003c\/td\u003e\n\u003ctd\u003e290 active (2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eTailored exclusively for McKesson, this Porter's Five Forces overview uncovers competitive drivers, supplier and buyer power, barriers deterring new entrants, substitutes and disruptive threats, and their collective impact on McKesson’s pricing, profitability, and strategic positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise Porter's Five Forces snapshot for McKesson—instantly highlights competitive pressures and supplier\/buyer dynamics to speed strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConsolidation of Retail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge retail customers—Walmart, CVS Health, and major hospital systems—account for roughly 40–50% of McKesson’s revenue; consolidation concentrates buying power into a few mega-buyers.\u003c\/p\u003e\n\u003cp\u003eThese buyers leverage combined annual purchasing volumes to extract lower distribution fees and extended payment terms; contract discounts commonly exceed 3–5% on drug spend.\u003c\/p\u003e\n\u003cp\u003eBy end-2025, market power is high: losing one national account can cut a distributor’s yearly revenue by mid-single-digit percentage points, materially hitting margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfluence of Group Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGroup Purchasing Organizations (GPOs) aggregate buying power of ~1,000s of hospitals and clinics—Premier Inc. and Vizient cover \u0026gt;40% of US hospital procurement—forcing distributors to bid on price and service; in 2024 GPO-negotiated contracts cut average drug\/device prices by 8–15%, limiting McKesson’s unilateral pricing and margin flexibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Reimbursement and Policy Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment payers like Medicare and the Department of Veterans Affairs are among McKesson’s largest buyers, directly or indirectly setting reimbursement benchmarks that influence roughly 40–50% of US prescription drug spending as of 2024.\u003c\/p\u003e\n\u003cp\u003eFederal and state drug-pricing laws passed in 2023–2025 pushed average distributor gross margins down by an estimated 100–200 basis points industrywide, compressing McKesson’s margin levers.\u003c\/p\u003e\n\u003cp\u003eBecause public-sector reimbursement terms are largely non-negotiable, McKesson must regularly update pricing models and contract terms to preserve ~2024 EBITDA margins near 2–4% in distribution segments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow Switching Costs for Generic Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn generics, buyers face low switching costs and can shift distributors for small price gains; retail pharmacies and hospitals commonly dual-source to secure savings. Generic drugs made up about 70% of US prescriptions in 2024, driving intense price sensitivity that compressed gross margins—McKessonʼs generic distribution saw EBITDA margins under 3% in FY2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh price sensitivity\u003c\/li\u003e\n\u003cli\u003eDual-sourcing common\u003c\/li\u003e\n\u003cli\u003e70% US prescriptions are generics (2024)\u003c\/li\u003e\n\u003cli\u003eEBITDA \u0026lt;3% in McKesson generics FY2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for Value-Added Digital Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern healthcare buyers now demand integrated analytics, inventory software, and clinical tools with distribution deals; McKesson faces customers who rate partners on tech ecosystems as much as on delivery.\u003c\/p\u003e\n\u003cp\u003eThis shift lets buyers push for richer service bundles without higher per-unit prices—survey data shows 62% of provider systems in 2024 prioritized digital capabilities when switching distributors.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of providers prioritized digital features (2024)\u003c\/li\u003e\n\u003cli\u003eDigital services reduce stockouts by ~20%\u003c\/li\u003e\n\u003cli\u003eBuyers push for bundled tech at flat unit pricing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuyer concentration, GPO cuts and generics squeeze margins — McKesson faces mid-single-digit risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyers hold high leverage: top retailers and hospital systems drive 40–50% of McKesson revenue, forcing \u0026gt;3–5% contract discounts and mid-single-digit revenue risk if a national account is lost; GPOs (Premier, Vizient) cover \u0026gt;40% hospital procurement and cut prices 8–15% (2024). Government payers set reimbursement affecting ~45% of drug spend; distributor gross margins fell ~100–200 bps due to 2023–25 laws; generics (70% of scripts, 2024) compress EBITDA \u0026lt;3%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTop buyers share of revenue\u003c\/td\u003e\n\u003ctd\u003e40–50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO hospital coverage\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO price cuts\u003c\/td\u003e\n\u003ctd\u003e8–15% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenerics of scripts\u003c\/td\u003e\n\u003ctd\u003e70% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistributor margin pressure\u003c\/td\u003e\n\u003ctd\u003e-100 to -200 bps (2023–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMcKesson generics EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMcKesson Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact McKesson Porter’s Five Forces analysis you’ll receive—no placeholders, no mockups—fully formatted and ready for download immediately after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747506958713,"sku":"mckesson-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/mckesson-five-forces-analysis.png?v=1772199386","url":"https:\/\/growthsharematrix.com\/products\/mckesson-five-forces-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}